Walleye Capital LLC Bei Gene, Ltd. Call Options Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $349,704 - $470,664	2,700 New	2,700 $385,000
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $79,335 - $100,790	500 Added 83.33%	1,100 $198,000
Q3 2023 Nov 21, 2023	BUY	$179.87 - $225.13 $107,922 - $135,078	600 New	600 $107,000
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $410,090 - $613,593	2,300 Added 230.0%	3,300 $588,000
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $43,106 - $54,900	200 Added 25.0%	1,000 $215,000
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $100,408 - $183,440	800 New	800 $175,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.